vt3989
vivace therapeutics
['mesothelioma', 'sarcoma', 'vt3989']
the investigational drug vt3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, a phase 1 study presented at aacr 2023 suggests. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.